Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 4;8:163. doi: 10.3389/fonc.2018.00163

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Pierpont, Limper and Richards.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Engineered differences between Food and Drug Administration approved anti-CD20 monoclonal antibodies (mAbs). Rituximab is a chimeric mAb that is partially humanized, that has a human Fc portion but retains the murine variable region which recognizes CD20. Both ofatumumab and obinutuzumab are fully humanized mAbs, which reduces unintended immune responses against the therapies. Ofatumumab also has a glycoengineered Fc region which results in better binding with immune effector cells (106, 190).